Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification

BMC Cancer

Table 2 Multivariable Cox regression analysis of overall survival, cancer specific survival, recurrence free survival

Parameter	Overall survival		Cancer specific survival		Recurrence free survival
Parameter	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
pT stage
T2	reference		reference		Reference
≥ T3	1.46 (1.15–1.85)	0.002	1.49 (1.17–1.90)	0.001	2.04 (0.38–10.74)	0.400
LVI	0.86 (0.25–2.93)	0.806	2.33 (0.44–12.16)	0.316	2.66 (0.97–7.65)	0.060
CIS	0.90 (0.28–2.89)	0.858	4.15 (1.21–16.03))	0.028	0.70 (0.43–1.14)	0.160
N stage		0.478		0.096		0.096
N0	reference		Reference		reference
≥ N1	1.71 (1.46–1.99)	< 0.001	1.75 (1.62–1.91)	0.004	2.96 (1.40–6.22)	0.004
CK5/6	3.30 (0.81–14.63)	0.101	2.57 (0.90–8.16)	0.088	3.15 (0.8–12.63)	0.104
CK14	6.16 (1.28–38.30)	0.033	3.96 (1.13–16.36)	0.040	3.19 (1.07–9.55)	0.037
GATA3	0.77 (0.37–1.58)	0.477	0.81 (0.22–2.89)	0.742	0.29 (0.01–5.27)	0.409
FOXA1	0.08 (0.01–0.59)	0.023	0.08 (0.01–0.61)	0.024	0.12 (0.1–1.51)	0.103

HR Hazard ratio, CI Confidence interval, LVI Lymphovascular invasion, CIS Carcinoma in situ, LND Lymph node dissection, LN Lymph node, UC Urothelial carcinoma

ISSN: 1471-2407